Adaptive Biotechnologies' COO Sells Shares via Option Exercise
Adaptive Biotechnologies' COO, Julie Rubinstein, sold 57,180 shares of the company's stock through the exercise of options, with a total transaction value of approximately $758,000. The sale represents 11.95% of her direct holdings, leaving her with 421,174 shares post-transaction. The sale occurred between April 9 and April 13, 2026, as disclosed in an SEC Form 4 filing.
Tickers: $ADPT
Topics: Adaptive Biotechnologies Corporation executive transactions SEC filings share sales